NO20032625L - Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer - Google Patents

Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer

Info

Publication number: NO20032625L
Authority: NO; Norway
Prior art keywords: indazolyl; kinase inhibitors; kinase; substituted pyrroline; compounds
Prior art date: 2000-12-08

Application number

NO20032625A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032625D0 (no

Inventor

Han-Cheng Zhang

Bruce E Maryanoff

Bruce Conway

Kimberly White

Hong Ye

Leonard R Hecker

David F Mccomsey

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-08

Filing date

2003-06-10

Publication date

2003-08-05

2003-06-10 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2003-06-10 Publication of NO20032625D0 publication Critical patent/NO20032625D0/no

2003-08-05 Publication of NO20032625L publication Critical patent/NO20032625L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Immunology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)

NO20032625A 2000-12-08 2003-06-10 Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer NO20032625L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25416600P	2000-12-08	2000-12-08
PCT/US2001/047689 WO2002046183A2 (en)	2000-12-08	2001-12-06	Indazolyl-substituted pyrroline compounds as kinase inhibitors

Publications (2)

Publication Number	Publication Date
NO20032625D0 NO20032625D0 (no)	2003-06-10
NO20032625L true NO20032625L (no)	2003-08-05

Family

ID=22963185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032625A NO20032625L (no)	2000-12-08	2003-06-10	Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer

Country Status (25)

Country	Link
US (4)	US6849643B2 (da)
EP (1)	EP1362047B1 (da)
JP (1)	JP2004515499A (da)
KR (1)	KR20040016828A (da)
CN (1)	CN1230434C (da)
AT (1)	ATE326464T1 (da)
AU (1)	AU2002230727A1 (da)
BR (1)	BR0116468A (da)
CA (1)	CA2431166A1 (da)
CY (1)	CY1106125T1 (da)
CZ (1)	CZ20031594A3 (da)
DE (1)	DE60119790T2 (da)
DK (1)	DK1362047T3 (da)
ES (1)	ES2263681T3 (da)
HU (1)	HUP0303855A3 (da)
IL (1)	IL156339A0 (da)
MX (1)	MXPA03005140A (da)
NO (1)	NO20032625L (da)
NZ (1)	NZ526356A (da)
PL (1)	PL362576A1 (da)
PT (1)	PT1362047E (da)
RU (1)	RU2003117078A (da)
WO (1)	WO2002046183A2 (da)
YU (1)	YU46603A (da)
ZA (1)	ZA200305239B (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL156339A0 (en) *	2000-12-08	2004-01-04	Ortho Mcneil Pharm Inc	Indazolyl-substituted pyrroline compounds as kinase inhibitors
JP2005508365A (ja) *	2001-10-29	2005-03-31	ネクターセラピューティックスエイエル，コーポレイション	プロテインキナーゼｃインヒビターのポリマー結合体
KR100974770B1 (ko)	2002-03-05	2010-08-06	일라이 릴리 앤드 캄파니	키나제 억제제로서의 퓨린 유도체
MXPA04008671A (es)	2002-03-08	2004-12-06	Lilly Co Eli	Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
DE60319364T2 (de) *	2002-05-08	2009-02-19	Janssen Pharmaceutica N.V.	Substituierte pyrroline als kinase inhibitoren
CA2488798A1 (en) *	2002-06-05	2003-12-18	Janssen Pharmaceutica N.V.	Substituted pyrrolines as kinase inhibitors
JP2006521386A (ja) *	2003-03-27	2006-09-21	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	キナーゼ阻害剤である置換ピロリン
HRP20050991A2 (en) *	2003-06-13	2006-09-30	Janssen Pharmaceutica N.V.	Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
AU2004275694B2 (en) *	2003-06-30	2008-03-06	Bizbiotech Co., Ltd.	Compounds, compositions and methods
WO2005027629A2 (en) *	2003-09-19	2005-03-31	Children's Hospital Medical Center	Regulation of cardiac contractility and heart failure propensity
CN1856475A (zh) *	2003-09-23	2006-11-01	默克公司	异喹啉钾通道抑制剂
AU2005309275A1 (en) *	2004-11-23	2006-06-01	International Biotherapeutic Research Inc.	Method of delivery of therapeutic metal ions, alloys and salts
US8017395B2 (en)	2004-12-17	2011-09-13	Lifescan, Inc.	Seeding cells on porous supports
JP2008526841A (ja)	2005-01-10	2008-07-24	アストラゼネカアクチボラグ	肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体
SE0500055D0 (sv)	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
AU2006227447A1 (en) *	2005-03-17	2006-09-28	Novartis Ag	N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-RAF kinase
CA2613889A1 (en)	2005-06-08	2006-12-14	Centocor, Inc.	A cellular therapy for ocular degeneration
WO2007008514A2 (en) *	2005-07-07	2007-01-18	Georgetown University	Inhibitors of glycogen synthase kinase 3
WO2007041195A2 (en) *	2005-09-29	2007-04-12	Janssen Pharmaceutica N.V.	Macroheterocylic compounds as kinase inhibitors
US8741643B2 (en)	2006-04-28	2014-06-03	Lifescan, Inc.	Differentiation of pluripotent stem cells to definitive endoderm lineage
US7741290B2 (en) *	2006-06-01	2010-06-22	The Board of Trustee of The Leland Stanford Juinior University	Method of preventing progression of hypertension-induced heart failure with PKC peptides
EP2125683B1 (en)	2006-12-19	2013-10-23	The Board of Trustees of the University of Illinois	3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders
AU2008216382A1 (en) *	2007-02-12	2008-08-21	Array Biopharma, Inc.	Novel inhibitors hepatitis C virus replication
US9080145B2 (en)	2007-07-01	2015-07-14	Lifescan Corporation	Single pluripotent stem cell culture
CA3114827C (en)	2007-07-31	2023-09-05	Lifescan, Inc.	Differentiation of human embryonic stem cells to pancreatic endocrine
CA2954431C (en)	2007-11-27	2021-08-24	Lifescan, Inc.	Differentiation of human embryonic stem cells to pancreatic cells
RU2551772C2 (ru)	2008-02-21	2015-05-27	Сентокор Орто Байотек Инк.	Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток
US8623648B2 (en) *	2008-04-24	2014-01-07	Janssen Biotech, Inc.	Treatment of pluripotent cells
AU2009267137A1 (en)	2008-06-30	2010-01-07	Centocor Ortho Biotech Inc.	Differentiation of pluripotent stem cells
MX2011004565A (es)	2008-10-31	2011-07-28	Centocor Ortho Biotech Inc	Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
MX2011004563A (es)	2008-10-31	2011-06-01	Centocor Ortho Biotech Inc	Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
BRPI0921996A2 (pt)	2008-11-20	2015-08-18	Centocor Ortho Biotech Inc	Métodos e composições para cultura e ligação de células em substratos planos.
EP3260534A1 (en)	2008-11-20	2017-12-27	Janssen Biotech, Inc.	Pluripotent stem cell culture on micro-carriers
KR101785626B1 (ko)	2009-07-20	2017-10-16	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 분화
EP2456862A4 (en)	2009-07-20	2013-02-27	Janssen Biotech Inc	DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
KR101786735B1 (ko)	2009-07-20	2017-10-18	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 분화
PH12012501254A1 (en)	2009-12-23	2012-11-05	Janssen Biotech Inc	Differentiation of human embryonic stem cells
BR112012017761A2 (pt)	2009-12-23	2015-09-15	Centocor Ortho Biotech Inc	diferenciação das células-tronco embrionárias humanas
US9969981B2 (en)	2010-03-01	2018-05-15	Janssen Biotech, Inc.	Methods for purifying cells derived from pluripotent stem cells
CA2799154A1 (en)	2010-05-12	2011-11-17	Abbvie Inc.	Indazole inhibitors of kinase
RU2663339C1 (ru)	2010-05-12	2018-08-03	Янссен Байотек, Инк.	Дифференцирование эмбриональных стволовых клеток человека
JP6133776B2 (ja)	2010-08-31	2017-05-24	ヤンセンバイオテツク，インコーポレーテツド	多能性幹細胞の分化
KR101836850B1 (ko)	2010-08-31	2018-03-09	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 분화
CA2809300A1 (en)	2010-08-31	2012-03-08	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
AU2012355698B2 (en)	2011-12-22	2018-11-29	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells into single hormonal insulin positive cells
RU2018128383A (ru)	2012-03-07	2019-03-14	Янссен Байотек, Инк.	Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
RU2018108850A (ru)	2012-06-08	2019-02-26	Янссен Байотек, Инк.	Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки
EP2928466B1 (en)	2012-12-10	2020-10-28	Centogene GmbH	Use of maleimide derivatives for preventing and treating leukemia
US10370644B2 (en)	2012-12-31	2019-08-06	Janssen Biotech, Inc.	Method for making human pluripotent suspension cultures and cells derived therefrom
EP4039798A1 (en)	2012-12-31	2022-08-10	Janssen Biotech, Inc.	Suspension and clustering of human pluripotent cells
SG10201707811XA (en)	2012-12-31	2017-11-29	Janssen Biotech Inc	Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
MX2015008577A (es)	2012-12-31	2015-09-07	Janssen Biotech Inc	Cultivo de celulas madre embrionarias humanas en la interfase aire-liquido para la diferenciacion en celulas endocrinas pancreaticas.
KR102162138B1 (ko)	2014-05-16	2020-10-06	얀센 바이오테크 인코포레이티드	췌장 내분비 세포에서 mafa 발현을 향상시키기 위한 소분자의 용도
GB201509885D0 (en) *	2015-06-08	2015-07-22	Ucb Biopharma Sprl	Therapeutic agents
MA45479A (fr)	2016-04-14	2019-02-20	Janssen Biotech Inc	Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
CN110392686A (zh)	2016-12-30	2019-10-29	频率治疗公司	1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
US10383881B2 (en)	2016-12-30	2019-08-20	Frequency Therapeutics, Inc.	1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
CN120365272A (zh)	2018-10-05	2025-07-25	安娜普尔纳生物股份有限公司	用于治疗与apj受体活性有关的疾病的化合物和组合物
JP2022520671A (ja)	2019-02-08	2022-03-31	フリークエンシー・セラピューティクス・インコーポレイテッド	耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
FI4097099T3 (fi)	2020-02-07	2024-07-30	Gasherbrum Bio Inc	Heterosyklisiä glp-1-agonisteja
IL322686A (en)	2023-02-16	2025-10-01	Gasherbrum Bio Inc	Heterocyclic glp-1 agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) *	1989-02-23	1989-04-05	Hoffmann La Roche	Substituted pyrroles
MC2096A1 (fr)	1989-02-23	1991-02-15	Hoffmann La Roche	Pyrroles substitues
DE4005969A1 (de)	1990-02-26	1991-08-29	Boehringer Mannheim Gmbh	Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de)	1990-02-26	1991-08-29	Boehringer Mannheim Gmbh	Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5624949A (en)	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
ATE456367T1 (de)	1993-12-23	2010-02-15	Lilly Co Eli	Proteinkinase c inhibitoren
SE9603283D0 (sv)	1996-09-10	1996-09-10	Astra Ab	New compounds
WO1999042100A1 (en)	1998-02-23	1999-08-26	Sagami Chemical Research Center	Cell death inhibitors
AU4929999A (en)	1998-07-30	2000-02-21	Japan Tobacco Inc.	Disubstituted maleimide compounds and medicinal utilization thereof
EP1119548B1 (en)	1998-10-08	2004-12-08	SmithKline Beecham plc	3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
IL156339A0 (en) *	2000-12-08	2004-01-04	Ortho Mcneil Pharm Inc	Indazolyl-substituted pyrroline compounds as kinase inhibitors
DE60319364T2 (de)	2002-05-08	2009-02-19	Janssen Pharmaceutica N.V.	Substituierte pyrroline als kinase inhibitoren
CA2488798A1 (en)	2002-06-05	2003-12-18	Janssen Pharmaceutica N.V.	Substituted pyrrolines as kinase inhibitors
RU2004135382A (ru)	2002-06-05	2005-06-27	Янссен Фармацевтика Н.В. (Be)	Замещенные пирролины в качестве ингибиторов киназы
JP2006521386A (ja)	2003-03-27	2006-09-21	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	キナーゼ阻害剤である置換ピロリン
HRP20050991A2 (en) *	2003-06-13	2006-09-30	Janssen Pharmaceutica N.V.	Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors

2001
- 2001-12-06 IL IL15633901A patent/IL156339A0/xx unknown
- 2001-12-06 CZ CZ20031594A patent/CZ20031594A3/cs unknown
- 2001-12-06 DK DK01990971T patent/DK1362047T3/da active
- 2001-12-06 PT PT01990971T patent/PT1362047E/pt unknown
- 2001-12-06 CN CNB018225675A patent/CN1230434C/zh not_active Expired - Fee Related
- 2001-12-06 AT AT01990971T patent/ATE326464T1/de not_active IP Right Cessation
- 2001-12-06 US US10/013,181 patent/US6849643B2/en not_active Expired - Lifetime
- 2001-12-06 DE DE60119790T patent/DE60119790T2/de not_active Expired - Fee Related
- 2001-12-06 JP JP2002547921A patent/JP2004515499A/ja not_active Ceased
- 2001-12-06 AU AU2002230727A patent/AU2002230727A1/en not_active Abandoned
- 2001-12-06 CA CA002431166A patent/CA2431166A1/en not_active Abandoned
- 2001-12-06 HU HU0303855A patent/HUP0303855A3/hu unknown
- 2001-12-06 ES ES01990971T patent/ES2263681T3/es not_active Expired - Lifetime
- 2001-12-06 RU RU2003117078/04A patent/RU2003117078A/ru not_active Application Discontinuation
- 2001-12-06 YU YU46603A patent/YU46603A/sh unknown
- 2001-12-06 MX MXPA03005140A patent/MXPA03005140A/es active IP Right Grant
- 2001-12-06 EP EP01990971A patent/EP1362047B1/en not_active Expired - Lifetime
- 2001-12-06 BR BR0116468-6A patent/BR0116468A/pt not_active IP Right Cessation
- 2001-12-06 KR KR10-2003-7007710A patent/KR20040016828A/ko not_active Ceased
- 2001-12-06 NZ NZ526356A patent/NZ526356A/xx unknown
- 2001-12-06 PL PL01362576A patent/PL362576A1/xx not_active Application Discontinuation
- 2001-12-06 WO PCT/US2001/047689 patent/WO2002046183A2/en not_active Ceased
2003
- 2003-06-10 NO NO20032625A patent/NO20032625L/no not_active Application Discontinuation
- 2003-07-07 ZA ZA200305239A patent/ZA200305239B/en unknown
2004
- 2004-07-06 US US10/885,373 patent/US7304060B2/en not_active Expired - Fee Related
- 2004-08-02 US US10/909,537 patent/US7329657B2/en not_active Expired - Fee Related
2006
- 2006-07-21 CY CY20061101017T patent/CY1106125T1/el unknown
2007
- 2007-12-13 US US12/001,805 patent/US7855203B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20080096949A1 (en)	2008-04-24
PT1362047E (pt)	2006-09-29
HUP0303855A2 (hu)	2004-03-01
JP2004515499A (ja)	2004-05-27
WO2002046183A2 (en)	2002-06-13
NZ526356A (en)	2005-02-25
EP1362047B1 (en)	2006-05-17
CY1106125T1 (el)	2011-06-08
CN1489586A (zh)	2004-04-14
DK1362047T3 (da)	2006-09-04
US20030055097A1 (en)	2003-03-20
US6849643B2 (en)	2005-02-01
US7855203B2 (en)	2010-12-21
CZ20031594A3 (cs)	2004-06-16
US20040259928A1 (en)	2004-12-23
US7304060B2 (en)	2007-12-04
NO20032625D0 (no)	2003-06-10
BR0116468A (pt)	2004-06-29
YU46603A (sh)	2006-05-25
WO2002046183A3 (en)	2002-09-06
DE60119790T2 (de)	2007-01-25
DE60119790D1 (de)	2006-06-22
ATE326464T1 (de)	2006-06-15
CN1230434C (zh)	2005-12-07
EP1362047A2 (en)	2003-11-19
IL156339A0 (en)	2004-01-04
HK1057370A1 (en)	2004-04-02
US20050004202A1 (en)	2005-01-06
CA2431166A1 (en)	2002-06-13
PL362576A1 (en)	2004-11-02
US7329657B2 (en)	2008-02-12
ZA200305239B (en)	2004-10-07
HUP0303855A3 (en)	2005-04-28
RU2003117078A (ru)	2004-12-10
KR20040016828A (ko)	2004-02-25
ES2263681T3 (es)	2006-12-16
AU2002230727A1 (en)	2002-06-18
MXPA03005140A (es)	2004-10-15

Publication	Publication Date	Title
DK1362047T3 (da)	2006-09-04	Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer
DE60323749D1 (de)	2008-11-06	Substituierte pyrroline als kinase inhibitoren
DE60319364D1 (de)	2008-04-10	Substituierte pyrroline als kinase inhibitoren
AU2737102A (en)	2002-06-18	Macroheterocylic compounds useful as kinase inhibitors
BG106585A (en)	2003-03-31	Kinase inhibitors as therapeutic agents
YU84603A (sh)	2006-03-03	Novi inhibitori tirozin kinaze
EA200300906A1 (ru)	2004-02-26	Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
MXPA03011907A (es)	2004-03-26	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
MXPA02005844A (es)	2004-08-12	Inhibidores de cinasas de proteina.
BR0208105A (pt)	2004-03-09	Inibidores de metaloproteinase
BR0308787A (pt)	2005-01-11	Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
IL151695A0 (en)	2003-04-10	Substituted beta-carbolines with ikb-kinase inhibiting activity
BRPI0412894A (pt)	2006-10-03	tienopiridina e furopiridina inibidores de quinases
EP1534695A4 (en)	2008-06-11	tyrosine kinase inhibitors
WO2004030620A3 (en)	2004-06-10	Novel tyrosine kinase inhibitors
BR0209149A (pt)	2004-07-13	Ftalazinonas
PL371127A1 (en)	2005-06-13	6-aminomorphinane derivatives, method for the production and use thereof
DE60329326D1 (de)	2009-10-29	Tace inhibitoren
DE60121587D1 (de)	2006-08-31	Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EP1496907A4 (en)	2006-05-10	Tyrosine kinase inhibitor
EP1496898A4 (en)	2006-05-10	Tyrosine kinase inhibitor

Legal Events

Date	Code	Title	Description
2007-08-13	FC2A	Withdrawal, rejection or dismissal of laid open patent application